Perspectives in Oncology Management and Research

https://pomr.cultechpub.com/pomr

Cultech Publishing

Review

Artificial Intelligence in Oncology: Advances in Cancer Diagnosis, Genomic Profiling, and Treatment Planning

Imran Khan Yousafzai[1,*], Aqsa Mehreen[1,*], Noor Fatima[2], Hawaida Ahmad[1], Nadia Noreen[3], Khadija Tariq[1,4]

[1]Department of Biological Sciences, National University of Medical Science, Rawalpindi, Punjab, Pakistan

[2]Department of Allied Health Sciences, National University of Medical Sciences, Rawalpindi, Punjab, Pakistan

[3]Department of Biological Sciences, Abasyn University, Islamabad, Pakistan

[4]Atta-ur-Rahman School of Applied Biosciences, National University of Science and Technology, Islamabad, Pakistan

[*]Corresponding author: Imran Khan Yousafzai, imranyousafzai37@gmail.com; Aqsa Mehreen, Aqsamehreen36@gmail.com

Abstract

Artificial intelligence (AI) has made significant advances in oncology, demonstrating excellent diagnostic accuracy in imaging, enhanced genetic interpretation, and decision-support capabilities for personalized therapy planning. Despite these advances, implementation in routine clinical practice remains limited and uneven. This review argues that the primary bottleneck is not algorithmic performance, but rather a persistent Clinical Embedding Gap, which disconnects model accuracy from real-world integration within clinical workflows, institutional infrastructure, incentive structures, and outcome-based validation frameworks. A structured narrative review was conducted. A systematic literature search was performed using PubMed/MEDLINE and Web of Science to identify relevant peer-reviewed literature published between 2015 and 2025. The findings suggest that AI systems are commonly performance-validated but insufficiently outcome-verified, which contributes to limited adoption. This gap must be bridged through workflow-native design, prospective clinical validation, interoperable digital infrastructure, and alignment of technological innovation with healthcare system readiness. Addressing these structural challenges is critical for advancing AI from experimental augmentation to integrated standard-of-care oncology practice.

Keywords

Artificial intelligence, Cancer diagnosis and treatment, Precision oncology, Medical imaging and histopathology, Ethical and clinical challenges

Article History

Received: 14 November 2025
Revised: 11 March 2026
Accepted: 20 March 2026
Available Online: 24 March 2026

1. Introduction

Cancer is one of the top causes of morbidity and mortality in the world, accounting for about 10 million deaths in 2020, according to World Health Organization (WHO) records [1]. Despite breakthroughs in early detection, imaging, molecular diagnostics, and therapeutic techniques, traditional oncology approaches are still constrained in numerous important aspects. Diagnostic interpretations are typically subjective and heavily reliant on human expertise; treatment approaches are often standardized rather than personalized, and integrating extensive multimodal data–spanning genomes, imaging, and clinical records–remains a significant challenge [2]. These restrictions contribute to delayed diagnosis, inferior treatment decisions, and inefficient resource allocation, emphasizing the critical need for scalable, adaptable, and data-driven approaches to cancer care [3]. Artificial intelligence (AI), including machine learning (ML) and deep learning (DL), has emerged as a computational framework capable of addressing these analytic constraints. Early cancer AI research, dating back to the 1990s, primarily focused on algorithmic decision-support tools and pattern recognition techniques [4]. As Figure 1 illustrates, the evolution of AI in cancer care across time demonstrates how AI applications advanced through four major periods from the 1990s to the 2020s. But recent improvements in DL and large-scale data integration have enabled more advanced predictive and diagnostic capabilities [5]. Despite promising performance metrics, translation into routine oncology practice remains limited [6]. Key barriers include data heterogeneity, limited annotated datasets, distribution shift, and restricted model generalizability across institutions [7]. Patient privacy, algorithmic bias, transparency, and responsibility are all important ethical and legal issues when establishing the viability and reliability of AI systems in therapeutic settings [8]. Furthermore, the successful translation of AI from research to everyday clinical practice necessitates rigorous validation, integration into current processes, clinician education, and regulatory compliance [9]. These concerns highlight the importance of a structured evaluation approach that assesses not only AI performance but also clinical readiness, safety, and scalability [10].

This review uses a bench-to-bedside translational approach to evaluate AI applications in oncology through three interrelated phases: technical development and algorithm validation, clinical assessment and workflow integration, and real-world implementation with system-level scalability. By applying this analytical lens across diagnostic, prognostic, and therapeutic areas, the review distinguishes between algorithmic promise and demonstrable clinical benefit. It critically examines not only technological performance but also the structural, ethical, and institutional factors that influence adoption. Finally, this approach enables a comprehensive evaluation of how AI may migrate from experimental tools to outcome-verified interventions in contemporary oncology practice.



Figure 1. Evolution of artificial intelligence in oncology over four decades. In the 1990s, AI was mostly used for early oncology research. During the 2000s, computer-aided diagnostic techniques helped diagnose cancer. In the 2010s, AI assisted with treatment planning and individualized care. In the 2020s, DL dramatically enhanced AI's involvement in precision oncology.

2. Methods

A structured narrative review was conducted to investigate the therapeutic applications, limitations, and translational issues of AI in cancer. A systematic literature search was conducted using PubMed/MEDLINE and Web of Science to locate relevant publications published between 2015 and 2025. The search approach blended controlled vocabulary with free-text terms related to AI and cancer, including: ("Artificial intelligence" OR "machine learning" OR "deep learning") AND ("oncology" OR "cancer") AND ("diagnosis" OR "screening" OR "treatment" OR "therapy" OR "drug discovery").

Peer-reviewed original research and review papers published in English that addressed clinical or translational applications of AI in human oncology, including outcomes related to diagnosis, prognosis, therapy, or implementation, were considered eligible. Excluded studies included non-English publications, conference abstracts without full text, editorials, opinion pieces, and research without therapeutic significance (e.g., purely computational or in silico studies without human data). After screening titles and abstracts for relevance, eligible studies were evaluated in full. Studies reporting verified models, comparisons with clinical standards, or real-world implementation were prioritized, although a formal risk-of-bias assessment was not performed due to the narrative approach. To promote transparency, qualitative synthesis considered study design characteristics (e.g., retrospective vs prospective, single-center vs multicenter

validation). In addition, more weight was put on studies with stronger evidence, particularly those with prospective and multi-center designs and patient-centered outcomes like survival, treatment outcomes, and decision impacts. In order to prove technological competency, retrospective and single-center studies with only algorithm performance metrics like accuracy and area under the curve (AUC) were considered; however, they were interpreted more cautiously in the evaluation of clinical studies.

Using qualitative data extraction and synthesis in different diagnostic and therapeutic areas, significant trends, barriers, and challenges in the clinical translation of AI in oncology were identified. The formal risk of bias approach was not employed since it is not compatible with the narrative synthesis approach of the review; however, the background and evidence of the methods were considered in the interpretation of the results.

3. AI in Early Cancer Detection and Screening

Early detection is a key part of effective cancer control because early detection is consistently linked to better survival, less illness, and lower healthcare costs. Improvements in imaging technologies have made screening programs more sensitive, but they have also increased the volume and complexity of data that doctors must interpret. In this context, AI has emerged as a supplementary analytical tool designed to improve precision detection, standardize interpretation, and reduce human variability in population-level screening initiatives [11]. An overview of the main AI application areas in cancer is given in Figure 2, which also shows how various AI technologies enhance drug development, treatment planning, and diagnostics.



Figure 2. Key applications of AI in oncology throughout the cancer care pathway. AI contributes to image-based diagnostics by improving the accuracy of medical image analysis, such as computed tomography (CT), magnetic resonance imaging (MRI), and pathology slides. In genomics and molecular diagnostics, AI aids in the interpretation of complex genetic data for precision medicine. Treatment planning uses artificial intelligence to enhance therapy selection and administration. Furthermore, AI improves early detection and screening, allowing malignancies to be diagnosed at an earlier, more treatable stage.

In the following sections, we describe AI applications in imaging, histopathology, and molecular diagnostics, highlighting their benefits and limitations.

3.1 Image-Based Diagnostics

The contribution of AI to image-based cancer diagnostics is best appreciated through the diverse functional roles that AI systems play within radiologic workflows, rather than through standalone cancer-specific applications. Broadly speaking, these functions include triage and workflow optimization, improved identification of subtle or occult disease, and extraction of quantitative imaging biomarkers. Each demonstrates a varying degree of evidentiary maturity and transformational potential [12].

AI in imaging can be used most immediately and clinically as a tool for decision support and triage. Large imaging datasets can be used to train DL systems that can highlight questionable regions, prioritize high-risk studies, and act as second readers within known diagnostic paths [13]. AI-assisted workflows have shown moderate increases in sensitivity and decreases in false positives in certain cohorts for screening mammography and low-dose CT for lung cancer. However, the makeup of the dataset, imaging procedures, and clinical knowledge all have a significant impact on these advances. Crucially, many systems do not operate as independent diagnostic agents; rather, they serve as augmentation tools. In this role, AI mainly improves productivity, standardizes interpretation, and lowers inter-observer variability; this is more of a gradual improvement than a paradigm shift in radiologic practice [14]. A second task is to detect subtle or occult illness patterns that humans may struggle to identify consistently. DL methods can distinguish diffuse, low contrast, or complicated spatial patterns associated with malignancy by extracting high-dimensional features from imaging data. Microcalcifications in dense breast tissue, small pulmonary nodules, and early-stage diseases that defy traditional visual criteria are also potential applications. While retrospective and reader-assisted studies indicate increased sensitivity, the relationship between improved detection and improved survival or morbidity is not well established. Increased sensitivity may result in higher false-positive rates, raising concerns about overdiagnosis and therapy. Thus, while AI is technically superior in certain detecting tasks, its clinical usefulness requires prospective outcome-based confirmation [15].

A more ambitious and potentially disruptive application is the development of quantitative imaging biomarkers using radiomics and deep feature modeling. Using computational phenotyping, these systems seek to describe tumor

heterogeneity, predict therapy response, and stratify prognosis rather than simply finding lesions. Such approaches move imaging beyond morphology and toward predictive modeling [16]. However, radiomic pipelines frequently suffer from inconsistent features across scanners, a lack of standardized preprocessing, and insufficient multicenter validation. As a result, despite considerable conceptual promise, the majority of imaging biomarker models are still under development and have not yet been routinely integrated into clinical practice [17]. Taken together, AI applications in image-based diagnostics represent a range of translational maturity. Triage systems are almost ready for real-world use; detection-enhancement techniques enable incremental diagnostic refinement; and quantitative biomarker models represent a more revolutionary but methodologically problematic frontier. From bench to bedside, numerous imaging AI systems have received technical validation; however, fewer have undergone rigorous prospective clinical assessment, and only a small number have demonstrated scalable application inside typical cancer procedures. Although imaging AI usually demonstrates good diagnostic accuracy, the majority of the supporting evidence comes from retrospective or reader-assisted research conducted in controlled validation environments. External validation has improved in recent years, but there are still few prospective multicenter trials that show clear gains in survival, interval cancer reduction, or cost-effectiveness. As a result, reported performance gains should be interpreted with caution unless they are supported by data at the outcome level [18].

3.2 Histopathology

In the context of the bench-to-bedside translational paradigm, the stage of technological development and early clinical validation of AI in digital histopathology has been reached. Although numerous DL architectures have demonstrated substantial diagnostic concordance with expert pathologists across various datasets, the prospective validation and deployment of such systems remain limited. Accordingly, most systems have been deployed in a supportive role for decision-making. Beyond radiologic imaging, AI is also transforming histopathology, where it is redefining the microscopic analysis of digitized tissue slides [19]. AI enables automated assessment of digitized slides, detecting morphological patterns associated with malignancy [20]. AI models can assist pathologists by grading tumors, identifying metastases, and producing repeatable evaluations [21]. Studies in prostate and breast cancer histopathology demonstrate that AI can achieve accuracy comparable to expert pathologists while accelerating slide review. Overall, AI-assisted histopathology helps standardize diagnosis, reduce workload, and improve the timeliness of clinical decisions [22]. The AI-based histological analysis also helps in tumor grading and prognostication to assess the heterogeneity of the tumor and identify the features associated with aggressive behavior [23]. This not only helps in the context of diagnosis but also in setting the course of treatment and prognosis. Additionally, AI enables a quicker review of the slides, and it is advantageous to the overloaded pathology departments, as well as giving a second opportunity for a second opinion in areas where there is no access to specialized staff. With the continued advancement of imaging and pathology processes, computer-aided AI will assist in standardizing the diagnosis, reducing human error, and giving faster and more precise cancer diagnosis, and eventually, improve patient outcomes with more informed and timely clinical decisions. Most AI applications in digital pathology have been tested using retrospectively curated whole-slide image datasets. While validation studies frequently show excellent diagnostic concordance with expert pathologists, there is little evidence of consistent performance across varied laboratories and clinical situations. Prospective, multicenter studies examining workflow impact and patient outcomes are still required to validate the broad therapeutic value [24].

3.3 Genomic and Molecular Diagnostics

In the translational pipeline, AI applications in genomic and molecular diagnostics are mostly at the technical discovery phase. ML algorithms have shown tremendous potential in identifying molecular subtypes, prognosis, and mutation identification in genomic sequencing. However, many of these algorithms are still in the phase of being validated by retrospective data, and their use in day-to-day clinical practice is still in its early stages [25]. Mutations, copy number variations, gene fusions, and epigenomic alterations are all characteristics of cancer, which is primarily a genetic illness. These molecular alterations are notable in adequate diagnosis and risk assessment along with selection of targeted therapy. The next-generation sequencing (NGS) and high-throughput sequencing technologies have potential to profile the cancer genome in order to get the detailed map and information [26]. However, the magnitude, multidimensionality and heterogeneity of omics data presents an ultimate challenge of the traditional modes of analysis [27]. In order to address these challenges, AI, particularly ML and DL are on the rise to extract clinically actionable information on genomic and molecular data [28]. Large numbers of genomic data can be analyzed by ML techniques to identify recurring mutations, tumor subtype classification, and patterns of gene expression that can be used to predict prognosis or therapy response [29]. ML algorithms can stratify patients based on gene expression or predicted therapy response. ML models, including support vector machines and random forests, have been applied to predict prognosis based on molecular profiles [30]. ML models, including support vector machines and random forests, have been applied to predict prognosis based on molecular profiles [31]. In order to find predictive biomarkers and guide individualized treatment choices, AI can incorporate multi-omics data [32]. AI is able to categorize tumors according to their molecular subtype in order to inform treatment and prognosis [33]. DL models, such as DeepVariant, improve mutation detection in NGS data, reducing false positives and increasing sensitivity compared to conventional pipelines [34].

A third territory with potential is the use of AI to identify minimal residual disease (MRD) using liquid biopsies.

Through the analysis of circulating tumor DNA (ctDNA) in blood samples through AI algorithms, minute amounts of tumor-specific mutations can be detected to diagnose the possibility of disease recurrence or resistance to therapy in an early stage. Such approaches allow early detection of recurrence and real-time monitoring of therapy response [35]. Studies show that ctDNA profiling can detect relapse months earlier than conventional imaging. AI can support precision oncology and customized treatment planning by integrating molecular, clinical, and imaging data. Such a comprehensive perspective promotes precision oncology where the treatment could also be adjusted specifically to each tumor work and to the specific molecular context of an individual [36]. Lastly, in rare cancer or pediatric oncology, where data is sparse, AI enables transfer learning and federated learning inference models to infer similar data with similar patients, whilst protecting the privacy of patients. These approaches facilitate research in rare cancers while maintaining patient privacy. Overall, AI-assisted molecular diagnostics complements imaging and histopathology, advancing precision oncology. With the further decrease in cost of sequencing and increasing accessibility, the application of AI in genomic and molecular diagnostics will only increase and revolutionize the molecular diagnosis of cancers as they are diagnosed and classified in this manner. AI-powered genomic and molecular analyses have demonstrated excellent performance in biomarker discovery and subtype categorization, primarily on research or curated datasets. However, many findings are still based on retrospective or in silico analysis, with fewer research showing actual improvements in therapeutic decision-making or survival outcomes. As a result, clinical translation remains diverse and requires additional prospective validation [37].

4. AI in Therapeutic and Management Oncology

4.1 Treatment Planning and Clinical Decision Support Systems

AI is transforming oncology by enabling individualized treatment strategies tailored to each patient's molecular and clinical profile. Traditional cancer care often relies on standardized treatment based on cancer type and stage, without fully accounting for patient-specific characteristics. AI addresses this limitation by integrating multiple data sources—including electronic health records (EHRs), genomic profiles, histopathology, prior treatments, and clinical outcomes—to support precision medicine [38].

Clinical decision support systems (CDSS) are one primary application of AI in individualized treatment. IBM Watson Oncology is a widely cited example: It leverages ML and natural language processing to analyze peer-reviewed literature, treatment guidelines, clinical trials, and real-world evidence, offering evidence-based treatment recommendations. Studies indicate that Watson's recommendations align with oncologists' decisions in over 90% of breast cancer cases, demonstrating its potential as a decision-support tool. Other AI-driven CDSS platforms include Tempus, which integrates molecular and clinical data to guide treatment selection; Foundation Medicine, which interprets genomic profiling for targeted therapy; and OncoKB, a precision oncology knowledge base that annotates mutations for clinical relevance [39].

While these systems offer significant promise, their use is not without limitations. Watson Oncology and similar platforms may be constrained by incomplete or biased training datasets, limited transparency in algorithmic decision-making, and variability in clinical adoption. Moreover, evidence supporting improved patient outcomes in routine practice remains limited. Clinicians must therefore interpret AI recommendations critically and consider them as supplements rather than replacements for professional judgment [40]. AI models can help clinicians with risk-benefit analysis and therapy selection in addition to CDSS. For instance, based on molecular subtypes and recurrence risk scores, AI can predict whether endocrine therapy will be more beneficial than chemotherapy in hormone receptor-positive breast cancer. To compare various treatment options, AI algorithms can also model outcomes like survival rates, progression-free survival, and the likelihood of adverse effects. This feature, which facilitates shared decision-making in line with patient preferences and objectives, is especially helpful for patients who are more likely to experience toxicity or treatment failure [41].

By forecasting biomarkers like PD-L1 expression, tumor mutation burden (TMB), and microsatellite instability (MSI), which determine the probability of response to immune checkpoint inhibitors, AI further customizes immunotherapy. AI integration of proteomic, genomic, and imaging data has demonstrated promise for improving immunotherapy response prediction in melanoma and non-small cell lung cancer. Similar to this, AI models trained on multi-omics data can identify subtypes of acute myeloid leukemia (AML) and forecast response to targeted treatments like FLT3 inhibitors [42].

Finally, AI is being applied to supportive care by predicting treatment-related side effects, including chemotherapy-induced neutropenia, cardiotoxicity, and fatigue. These predictions allow proactive interventions and dose adjustments, reducing adverse events and improving patient quality of life [43]. Despite these developments, there are still several obstacles to clinical AI adoption in treatment planning, such as restricted access to high-quality training data, algorithm transparency, regulatory approval, and integration with electronic health infrastructures. It is anticipated that AI technologies will become essential to personalized oncology, improving patient-centered care and optimizing therapeutic outcomes as they develop and validation studies mount. Expert oncologists and AI-based decision support systems are often reported to have excellent concordance; nevertheless, concordance by itself does not ensure better patient outcomes. Instead of proving independent clinical benefit, the majority of reviews have been observational and

retrospective, frequently indicating agreement with existing standards. There is still a lack of prospective outcome-driven validation [44].

4.2 Radiation Therapy

Radiation therapy (RT), a crucial part of cancer treatment, requires careful planning to ensure the best potential therapeutic outcomes. The primary objective of RT is to deliver a therapeutically effective radiation dosage to the tumor while minimizing exposure to adjacent healthy tissues and organs at risk (OARs). Achieving this balance requires precise tumor identification, appropriate dosage computation, and the ability to account for anatomical variations throughout treatment. Conventional RT planning is labor-intensive, manual, and prone to inter-observer variability. These restrictions may have an impact on the effectiveness and consistency of planning, especially in complicated situations. Several elements of the RT planning workflow can now be supported and standardized with the use of AI [45]. Auto-segmentation is one of the most well-known uses of AI in radiation oncology. Tumor volumes and OARs on imaging modalities including CT and MRI are delineated using DL models, namely convolutional neural network (CNN) and U-Net-based architectures. While retaining accuracy on par with professional human delineation, AI-assisted segmentation increases contouring consistency and lessens the workload for clinicians. To facilitate segmentation in disease locations like lung, prostate, and head and neck malignancies, a number of commercial solutions have been included into clinical workflows [46]. AI has also been used for dose adjustment and planning. To meet dosimetric restrictions, traditional inverse planning relies on iteratively adjusting planning parameters. On the other hand, ML-based methods predict dosage distributions based on patient-specific anatomy by learning from previously approved treatment plans. These techniques seek to decrease planner variability while increasing planning effectiveness and quality. Sequential optimization of dosage distributions is also being investigated using reinforcement learning techniques, albeit these approaches are still mostly in the research stage [47]. Adaptive radiotherapy (ART) is another significant area of application. ART entails adjusting treatment regimens in response to anatomical changes that occur throughout the course of treatment, such as tumor regression, weight loss, or organ movements. AI facilitates prompt plan adaptation by enabling automated analysis of longitudinal imaging data to identify pertinent anatomical changes. This strategy may lessen radiation-related harm and increase treatment accuracy [48]. AI-based models are also being created to forecast treatment outcomes, such as the risk of radiation-induced toxicity and local tumor control. These models may help doctors balance treatment benefit against potential damage by combining imaging, dosimetric, and clinical variables, especially in complex or borderline clinical settings. Despite its potential, stringent validation and supervision are necessary for the practical integration of AI in RT planning. To guarantee safe and efficient deployment, issues with algorithm transparency, generalizability across institutions, data quality, and regulatory approval must be resolved. Therefore, rather than taking the role of clinical competence, AI-based technologies should be seen as decision-support systems [49]. When used in a scientifically verified and clinically supervised framework, AI has the potential to improve RT planning's overall consistency, efficiency, and adaptability. In retrospective plan-comparison studies, AI-assisted radiation planning has shown increases in dosimetric consistency and contouring efficiency. Although process improvements are encouraging, there is currently a lack of solid prospective data connecting these techniques to better tumor management or lower toxicity. Before routine implementation may be regarded as final, multicenter validation is necessary [50].

4.3 Surgical Oncology

AI is increasingly influencing surgical oncology and its influence on the preoperative planning, intraoperative navigation, and postoperative tests [51]. In preoperative stage, AI algorithms work with high-resolution imaging data, which reduces (though does not eliminate) the likelihood of uncertainty in tumor boundary delineation by surgeons and enables them to see structural changes, anatomical abnormalities, and the proximity of tumours to healthy organs. This assists in the that are aimed at achieving maximal oncologic resection while preserving healthy tissue [52]. Characteristics of radiomics can also be fitted on clinical and histological information to forecast tumor conduct and impact the level of resection to be performed with the aid of the AI-based tools. The AI driven navigation systems provide real time assistance during surgery by superimposing the preoperative images on the operating field [53]. Surgeons can visualize tumor tissue margins, identify critical structures and remain orientated on complex procedures. Therefore, such systems remain limited to selected clinical settings and require careful validation to ensure reliability under dynamic surgical conditions. More AI has also been utilized in the operating room due to the field of robotic assisted surgery. Currently, such systems as the da Vinci Surgical System are empowered with AI modules that enable the systems to enhance precision, steadiness and visibility. Table 1 highlights representative robotic surgical platforms with AI-enabled functions and their clinical uses. While surgical control remains entirely with the operator. AI will help to enrich the recognition of gestures, tracking of instruments and workflow analysis [54].

In addition, ML algorithms can also be used to predict postoperative or intraoperative complications. Such models can predict patient-specific risk predictors of bleeding, infection, anastomotic leak, and slow recovery using enormous amounts of past surgery information. This prediction may support preoperative risk stratification and contingency planning. Another role of AI in skill and training surgeons is also involved [55]. Robotic systems can also offer information on motion-tracking, which can be used to evaluate surgical performance and provide program assistance feedback to trainees. Such abilities as the dexterity of using the tool and the time-saving can be quantified and

transferred to personalized skill development. The usage of AI in postoperative image analysis enables the early detection of these results of the operation as remaining cancerous tissue, hematoma, or the appearance of other aberrant healing. It can also be useful during longitudinal follow-up because post and pre-operative scans can be compared with the help of AI to trace recurrence or to the adjuvant therapy [56]. Despite these advancements, AI is implemented in surgical oncology but the challenges that should be addressed are good validation, surgeon education, and integration with existing hospital-based systems. Ethical and regulatory considerations emphasize the need for a human-in-the-loop framework, with surgeons retaining full responsibility for clinical decisions. In conclusion, AI-based tools can improve surgical planning and guiding when used as clinician-supervised decision-support systems. Their safe and successful usage requires rigorous validation, proper training, and clear accountability mechanisms. Single-center observational data and feasibility studies provide strong support for AI applications in surgical oncology. Although reductions in operative time or complication rates have been reported, scalability and reproducibility across institutions remain uncertain. There is currently little data showing long-term benefits in oncologic outcomes [57].

5. Implementation in Clinical Practice

5.1 Drug Discovery

Drug discovery and development in oncology is a complicated, resource-intensive process with long deadlines and significant attrition rates, especially in late-stage clinical trials. Biological heterogeneity, preclinical models' poor predictive ability, and unexpected toxicity or ineffectiveness in human populations are the causes of these difficulties. In this regard, rather than taking the place of traditional experimental and clinical approaches, AI has emerged as a complementary tool with the potential to improve stages of the drug development pipeline. AI-based models are increasingly being used to enhance target selection and validation in large-scale biological datasets during the early stages of drug discovery. ML algorithms can find potential molecular targets linked to oncogenic pathways and tumor-specific vulnerabilities by combining genomic, transcriptomic, proteomic, and metabolomic data. Although these methods can identify subtle patterns in high-dimensional data, their results are still heavily reliant on biological relevance, annotation consistency, and data quality, hence experimental validation is required before translational application [58].

Molecular design and virtual screening have also utilized AI. Large chemical libraries can be computationally assessed by DL models to rank compounds according to their expected binding affinity, selectivity, and structural compatibility with target proteins. It has been shown that generative models, such as adversarial networks and reinforcement learning frameworks, can suggest new chemical structures with predetermined pharmacological limitations. The gap between computer optimization and biological complexity is highlighted by the fact that many AI-generated candidates are still in the silicon or early preclinical stages, and their prediction accuracy does not always translate into clinical success [59]. Several biotechnology companies, including BenevolentAI, Insilico Medicine, and Atomwise (Table 1), have used AI systems in their oncology drug discovery initiatives. While these programs demonstrate the scalability and effectiveness of AI-driven workflows, most reported outcomes are for target identification or preclinical candidate nomination, rather than clinically licensed treatments. As a result, these examples should be viewed as proof-of-concept demonstrations rather than evidence of established clinical impact. Transparent reporting of validation procedures and failure rates is still restricted across the sector [60]. Beyond discovery, AI is increasingly being utilized to optimize pharmacokinetic and pharmacodynamic (PK/PD) profiles, as well as predict absorption, distribution, metabolism, excretion, and toxicity. These predictive techniques can help to prioritize molecules with better safety and effectiveness characteristics, potentially lowering attrition throughout preclinical development. However, the representativeness of training datasets limits algorithmic predictions, and they may fail to catch infrequent or long-term toxicity found in varied patient populations. AI is also influencing clinical trial design and execution. AI-based solutions can help with patient stratification, eligibility matching, and trial enrollment optimization by analyzing EHRs, genomic repositories, and real-world data. Predictive analytics can help inform adaptive trial designs by identifying subgroups that are more likely to benefit from specific interventions. While these technologies improve efficiency, ethical issues such as bias, data privacy, and equitable patient representation must be properly addressed. Another developing application of AI is post-marketing surveillance, which uses natural language processing algorithms to assess real-world information, such as clinical notes and adverse event reports, in order to uncover unusual or delayed toxicities. Such tools may supplement existing pharmacovigilance systems, but they require strict regulatory control to assure reliability and interpretability. Major pharmaceutical corporations, including Pfizer, Novartis, and Roche, have integrated AI techniques into various stages of their research and development processes. Despite increasing popularity, issues with data standardization, algorithm transparency, reproducibility, and regulatory acceptability continue to be significant impediments to widespread application. Collaborative frameworks involving physicians, AI developers, industry stakeholders, and regulatory agencies are required to ensure that AI-driven approaches are reliable, explainable, and clinically relevant. To summarize, AI is altering several aspects of oncology drug discovery and development by improving target identification, compound prioritization, and trial efficiency. However, its current impact is more supporting than revolutionary, with the majority of applications requiring considerable experimental and clinical confirmation. A cautious, evidence-based strategy is thus required to convert AI-driven innovation into safe and effective cancer therapeutics. AI has mostly improved early-stage target identification and virtual screening procedures

in oncology medication development. Relatively few AI-derived drugs advance to late-stage clinical validation or regulatory approval, with the majority of reported advancements remaining preclinical. As a result, rather than being completely realized, the translational impact of AI on drug discovery is still in its early stages [61].

5.2 Case Studies

Several clinical fields have investigated the use of AI, demonstrating its ability to improve diagnostic accuracy and patient care. Cancer screening and management have been the most extensively researched, providing useful insights into AI's real-world performance. The case studies below highlight major implementations in breast and prostate cancer.

5.2.1 Breast Cancer Screening

Breast cancer screening is one of the most widely researched clinical uses of AI in oncology. Mammography remains the primary method of population-level breast cancer screening; nevertheless, its diagnostic accuracy is lowered in patients with dense breast tissue and is influenced by reader variability. Even highly skilled radiologists may miss minor cancer characteristics or produce false-positive results, emphasizing the importance of complementary analytical tools. Google Health conducted a significant study, published in Nature in 2020, that examined an AI system trained on big mammogram datasets from the United States and United Kingdom. Under controlled study conditions, the model performed diagnostically comparable to experienced radiologists. Specifically, the approach reduced false-positive rates by 5.7% in the United States and false-negative rates by 9.4% in the United Kingdom when compared to standard clinical interpretation. These findings show that AI may help to enhance diagnostic consistency and eliminate unnecessary reminders, while external validation across many clinical settings is still required [62]. Furthermore, Figure 3 shows that both AI and radiologist sensitivity decrease with increasing breast density, emphasizing the ongoing masking impact of dense tissue on mammographic detection. The high agreement between AI-predicted and radiologist-assigned ACR density supports the use of AI for standardized density evaluation and informed screening decisions.



Figure 3. Sensitivity AI and radiologists by breast density. (A) Sensitivity of the AI system across ACR breast density groups, showing decreased sensitivity with increasing breast density. (B) Agreement between radiologist-assigned ACR density and AI-predicted density, illustrating the proportion of agreement and disagreement for each ACR category.

In practice, AI-based mammography tools are being evaluated as decision-support systems than as autonomous diagnostic solutions. Pilot deployments, including assessments in the UK's National Health Service, have investigated AI as a supplementary reader within established screening workflows. While such technologies may assist in decreasing reader fatigue and variability, the ultimate diagnostic duty remains with human professionals [63]. Importantly, AI models may be trained using population-specific data, allowing for some adaptability to demographic and imaging diversity, such as breast density distributions. Emerging research has also investigated using AI-derived risk stratification to inform personalized screening intervals, but these tactics need to be prospectively clinically validated before they can be widely adopted. Despite promising results, implementing AI-enhanced mammography confronts several hurdles, including workflow integration, regulatory approval, algorithmic decision-making openness, and clinician trust. Furthermore, stated performance gains are highly dependent on training data composition and study methodology, underlining the importance of continuous post-deployment monitoring. Overall, AI-enhanced mammography is a clinically advanced and evidence-based application of AI for cancer screening. Its greatest value resides in supplementing, rather than replacing, radiologist skill, with long-term therapeutic benefit dependent on rigorous validation and prudent integration into screening programs [64].

5.2.2 Prostate Cancer Management

Prostate cancer is still among the frequent cancers in men, and the diagnosis and therapeutic treatment of this condition entails the use of multidisciplinary teams comprising of imaging, laboratory tests, pathology, and clinical opinion. The recent innovations in AI have introduced profound transformations to the process of diagnosis, evaluation and treatment of prostate cancer and thus giving it a more accurate and customized management [65]. Among the most significant

diagnostic methods as far as prostate cancer is concerned, there is the multiparametric MRI (mpMRI) which provides the images of the prostate region and adjacent tissue, specifically. The AI algorithms were expounded to assist in interpretation of mpMRI to detect and describe suspicious lesions and eliminate the necessity of subjective assessment by radiologists. These are uber-large, annotated data AI tools that learn and can observe very minor features that the human eye cannot discern. The systems to which they have been applied include prostate imaging reporting and data system (PI-RADS) where similar scoring has been shown to be repeatable and inter-ratio agreement of radiologists has been shown to increase and decreasing diagnostic heterogeneity has been shown to decrease. Other than imaging, AI is another direction that the field of pathology is evolving in prostate cancer. The inter-observer, as well as the rate of variation in grading prostate biopsies, especially the Gleason score, has been found to be highly ubiquitous with reference to the conventional method of grading prostate biopsies by conventional histopathological means. Digital pathology based on AI is capable of automatically obtaining cancerous tissue and providing a grade to whole-slide images. The CNN form the basis of the systems to classify glandular architecture, nuclear features, and other microscopic features and give objective and standardized ratings, which enhance the precision of diagnoses [66]. One can find several publications that testified to the equality of the AI models and their even greater efficiency at the recognition and classification of prostate tumors compared to the efficiency of pathologists themselves. There is also another significant use of AI to risk stratify and plan the treatment. The best management recommendations based on the AI-based decision support systems can be tailored to the patient using data of mpMRI, pathology reports, PSA level, genomics, and the health records of patients. These can include the option of active monitoring of low-risk ones, or radical treatment, which can be surgery or radiation, in the case of more aggressive tumors. Disease state Changes modeling in terms of probability of progression, remission and complications of care It models risk and assists in shared decision-making between clinicians and clinicians. Moreover, there is also the development of AI real-time guidance that should be used during such procedures as MRI-ultrasound fusion-guided biopsies. Lesions would be targeted with better precision with the use of AI, biopsy results would be increased, and unnecessary tissue sampling would be minimized. Accurate contouring of prostates with OARs can be attained with the help of AI and it is applicable with radiation oncology with the most beneficial radiation dose and minimal toxicity. Several leading institutions, which have incorporated AI into the framework of treating prostate cancer and commercial solutions to enable clinical integration, are becoming more common. However, concerns such as compatibility of the platform across devices, data privacy, authorization and training of doctors will be required to be sorted out to enable it to be used extensively. Overall, AI has an opportunity to transform the management of prostate cancer by enhancing the quality of its diagnosis and allows customized therapy decisions and patient outcomes throughout the care pathways [65,67].

5.2.3 Real World Example: IBM Watson Oncology

One of the initial general attempts at trying to bring AI to clinical oncology is IBM Watson Oncology (Table 1). Watson for Oncology is an AI-based clinical decision support system meant to help oncologists find treatment alternatives that are compliant with guidelines [68]. The application of Watson in assisting the treatment of cancer, which is one of the most important cases of Watson use in the real world, occurred in Manipal Hospitals in India. The retrospective analysis was conducted by comparing the recommendations on the proposed recommendations of Watson with those recommended by experienced oncologists for breast, lung, and colorectal cancer patients. The walk-through study showed that there was a high concordance rate where agreement occurred in 93 percent in breast cancer, 88 percent in colon cancer, and 73 percent in lung cancer. However, concordance shows agreement with local clinician judgments rather than better patient outcomes, and retrospective evaluations are impacted by institutional practice patterns. These are some of the outcomes for which Watson can offer viable suggestions that can be accepted by the guidelines, particularly about common malignancies that have duly defined in the treatment guidelines. However, Watson has not performed ubiquitously in any institution or cancer. Some of the challenges that were experienced in some hospitals in China and in the United States included the fact that the system is of low capacity to absorb local therapy regimes, the disparity in access to up-to-date regional data, and inconsistency between AI-suggested recommendation and the preferences of oncologists every now and then. To be more specific, situations where the local epidemiology, patient preferences, or comorbidities played a significant role in the decision were poorly handled by the AI [69]. These limitations of implementation in Watson point out part of the larger concerns with the development of the adoption of AI tools in clinical practice. The first one is that localized training can not be underestimated: the use of AI systems will have to be localized to the existing clinical guidelines, patients and drugs available in the area. Second, it must be incorporated into EHRs, workflow compatibility, where long adoption is now in effect and keeps the integration in more seamless mode with a clinical routine. The real-world deployment of Watson for Oncology shows that successful clinical adoption is strongly reliant on localization to regional treatment recommendations, the availability of licensed medications, and connection with current EHR systems. Limited flexibility to local healthcare practices and inadequate workflow integration hindered usability in a variety of situations. These problems demonstrate that effective AI implementation in oncology necessitates not only algorithmic accuracy, but also contextual flexibility, transparency, and clinician trust [70].

Notwithstanding these challenges, several organizations are still investigating the possibility of Watson as an aid to education and a second opinion generator, especially in the limited resource environment. It cannot substitute oncologists but can supplement clinical decision-making, to bring evidence-based information to the fore. Also, future versions of such systems could be improved by the continued emergence of newer, more adaptable AI models that

acquire knowledge both locally and based on immediate feedback. To summarize, the introduction of the IBM Watson for Oncology is a useful case study on the potential and complications of applying AI to real-world oncology. Overall, IBM Watson for Oncology is a cautionary case study that demonstrates both the potential and limitations of AI-based decision support in real-world oncology practice [71].

Table 1. Applications of AI in cancer diagnostics and treatment.

Application Area	AI Technology Used	Key Benefit	Outcome (Quantitative)	References
Mammography	DL (CNN)	Improved early detection accuracy	In comparison to radiologists alone, Google Health AI (Nature, 2020) reduced false positives by 5.7% in the US and false negatives by 9.4% in the UK.	[72]
Histopathology	ML	Faster, more consistent tumor grading	Prostate/colon histopathology: 30%-40% faster diagnosis time; inter-observer grading variability decreased from 25% to <10%.	[73]
Genomic Analysis	AI for NGS data	Biomarker discovery, risk prediction	RNA-Seq AI techniques revealed 12 unique prognostic biomarkers for breast cancer (predictive AUC = 0.82).	[74]
RT Planning	Auto-segmentation models	Dose optimization, treatment precision	Varian Ethos AI: 50% reduction in contouring time; mean dosage to organs-at-risk decreased by 8%.	[74]
Surgical Planning	AI + Imaging + Robotics	Safer, minimally invasive procedures	da Vinci + AI navigation: 20% reduction in operative time and 15% lower complication rate in prostatectomies.	[75]
Drug Discovery	ML models for target ID	Faster pre-clinical development	Benevolent AI/Atomwise predicts 5 unique targets: *in vitro* validation success rate 60%.	[76]
Clinical Decision Support	NLP + ML	Personalized treatment recommendations	IBM Watson for Oncology: concordance with experienced oncologists: 93% breast, 88% colon, and 73% lung.	[77]

5.3 Comparative Studies vs. Human Experts

A significant number of these studies have compared the diagnostic accuracy of AI systems to a highly qualified human clinician particularly in the domains where pattern recognition and early-detection capabilities were critical. They have proved to be the research studies of choice in establishing clinical utility of the AI tools besides winning the trust of medical specialists. One such example is the Stanford University whereby the researchers developed a DL to identify the lung nodules using low dose computers tomography (LDCT) scans. The AI model was trained using thousands of annotated pictures and contested with a panel of board-certified radiologists [78]. The resultant outcomes were that AI system was as effective or more effective than radiologists to detect malignant nodules and significantly reduced false positives. It is a good pointer to the progress made in lung cancer screening where an earlier and right diagnosis can alter the fate of a person considerably. A second study in the dermatology sector published in Nature that used a CNN was an evaluation of its capacity to identify skin cancer (including melanoma) compared to 21 board-certified dermatologists. The AI model presented less or comparable results of dermatoscopic images in the categorization of malignant and benign lesion in the pictures. The findings outline the advantage of the application of AI as a new and efficient aid in triage during the primary care or teledermatology setting and in the rural or underserved area where only few specialists are available. In the scan of the retina, Google DeepMind came up with a machine AI-based imaging system capable of detecting over 50 eye ailments in the ophthalmology field [79]. It is possible that with automated eye disease screening, using the AI model, a professional ophthalmologist is not required because the model provided equal sensitivity and specificity to the task of a medical professional. Pathology has also not been very weak in comparison. It has also been demonstrated that DL algorithms based on digitized histopathology slides are accurate when it comes to identifying breast cancer in lymph node based on levels dependent on the experience of a trained pathologist. The TUPAC16 challenge and CAMELYON16 competition represented international-level competitions, where AI systems competed with expert human performance seeing how they worked, which serves to once again demonstrate the capability of AI to be diagnostic. Despite all these excellent findings, comparative studies should be taken with a grain of salt. Numerous studies are conducted under a controlled and retrospective setting where sterile data impose additional restrictions of what can or cannot help giving sufficient knowledge on the splendor and diversity that is available in more realistic clinical practice. The functionality of the models can be influenced by the quality of the images, other conditions that the patient may have, demographics of the patient and the changes in equipment [80]. In real bye settings, AI models often do not do well at identifying situations in which they are not sufficiently calibrated, updated, or supported on local data sets. In addition, state-of-the-art models of AI are more inclined to focus on limited, narrow tasks, and clinicians consider broader sets of clinical data and patient history. Hence, it is impossible to state that AI can be a replacement for clinicians but a kind of extension of them, which assists them in offering additional analysis to human decisions. The most popular solution, it seems, is a kind of hybrid one when AI predictions will be

incorporated with physician supervision, making the most out of AI. The models include the benefits of AI in processing information and identification of trends and patterns, and human supervision to appeal to ethics and the application of contexts. Pilot studies have shown that these types of synergistic models have better diagnostic outcomes. In conclusion, even though AI research is proving to be effective in comparative studies of its diagnostic power, the secret of its successful implementation will be a well-thought-out implementation of this technology, an ongoing verification of its effectiveness, and a combination of work processes based on the synergy of machine intelligence and human knowledge [81].

6. Comparative Translational Maturity Across the AI Domain

The translational maturity of AI in oncology varies significantly between domains due to differences in data structure, regulatory processes, validation standards, and workflow integration, rather than algorithmic capabilities alone. Although technological developments are common, routine clinical adoption is patchy. Image-based diagnostics, notably in radiology, are the most established field. Imaging data is digitally native, standardized, and accompanied by explicit performance indicators like sensitivity and AUC. Regulatory channels for software-based medical devices are quite well established, and many tools play an assisting role in existing processes [82]. These fundamental features—standardization, measurable outcomes, and shorter validation cycles–have allowed for relatively rapid clinical translation. Digital histopathology and genomics show strong algorithmic performance but sluggish integration. Scalability is limited by the variability of digital pathology infrastructure and laboratory operations, whereas genomic applications frequently rely on curated or retrospective data. Prospective trials indicating improvements in survival or therapeutic outcomes are scarce, and interpretability issues hamper routine implementation. The translational gap is noticeable in oncology medication discovery [83]. While AI improves early-stage target identification and chemical screening, drug development requires long, multi-phase clinical pipelines with significant attrition rates. The lengthy period between computer prediction and regulatory approval limits the speedy proof of patient-level benefit. Clinical decision assistance systems fall somewhere between two extremes. Although high concordance with expert suggestions is routinely reported, it does not always imply better outcomes, as adoption is influenced by workflow, trust, and medico-legal factors. In general, domains with uniform data, clearly defined ends, and shorter feedback loops have moved more quickly toward implementation. Recognizing these structural distinctions allows for a more realistic assessment of AI's existing influence and emphasizes where future validation efforts should be focused [84].

7. The Clinical Embedding Gap in AI-driven Oncology

Although the level of translational maturity of AI in these fields of oncology has been compared in the above section: Comparative translational maturity across the AI domain, there remains a critical cross-cutting challenge that has not been fully addressed until this point: the challenge of integrating even the best AI solutions into the normal course of practice. The therapeutic Embedding Gap in AI-Driven Oncology refers to the continuing disparity between high algorithmic performance and little real-world therapeutic impact. While AI systems in cancer imaging, pathology, genomic profiling, and treatment planning commonly achieve expert-level accuracy in retrospective or controlled validation studies, their implementation in ordinary oncology practice is variable. This mismatch indicates that the fundamental obstacle is not computational capabilities alone, but rather the challenge of effectively integrating AI tools into established clinical ecosystems [85]. Even solutions like IBM Watson Oncology, which shown significant concordance with oncologists, faced challenges due to workflow disruption, contextual variability, and limited adaptation across institutions. The disparity remains because AI adoption is based on more than just prediction accuracy. Effective implementation necessitates compatibility with EHRs, alignment with reimbursement and incentive systems, prospective outcome-based validation, regulatory clarity, and digital maturity. Many systems are still performance-validated (as measured by metrics like AUC or concordance), but there is insufficient evidence to show increased survival, cost-effectiveness, or patient-centered outcomes. Thus, the translational difficulty in AI oncology reflects a bigger system-level issue: algorithmic preparedness frequently outstrips institutional and clinical preparation, preventing AI from progressing from experimental augmentation to entrenched standard-of-care practice [86].

8. Critical Challenges

AI has shown great promise in several areas of cancer care; nevertheless, its routine clinical use is complicated by a number of interconnected difficulties. As seen in Figure 4, issues of data privacy and governance, restricted model interpretability, and clinical integration challenges all contribute to the translational gap between algorithmic performance and real-world clinical impact. These issues are not isolated, but rather span technical, ethical, regulatory, and implementation dimensions. The next subsections group these limitations into four essential categories: technical, interpretability, ethical/legal, and validation and adoption, emphasizing how they all limit the scalability and sustainability of AI-driven oncology solutions. The restrictions to AI integration in oncology are not separate hurdles, but rather interwoven structural issues that contribute to the Clinical Embedding Gap. Models trained using non-representative datasets (Technical Challenges) may result in skewed or unstable performance across institutions. When such systems lack transparency (interpretability), clinician credibility suffers, particularly in high-risk judgments. Reduced trust, along with ethical and legal uncertainty, directly impedes workflow integration and prospective

validation. These obstacles reinforce one another, resulting in a feedback cycle that limits real-world implementation despite great retrospective performance [87].



Figure 4. This figure illustrates the key independent challenges related to the effective utilization of AI in cancer care. These include data privacy issues related to sensitive information, the 'black box', and logistics related to interpretability. These three pillars represent the key necessity for the effective utilization of AI in cancer care.

8.1 Technical Challenges

Despite significant methodological advances, technical restrictions remain a major impediment to the reliable use of AI in cancer. Models trained on retrospective single-center datasets have limited generalizability, which decreases performance when applied to varied real-world populations [88]. Variations in imaging processes, staining techniques, sequencing platforms, and population demographics frequently result in performance loss when models are used outside of development environments [89]. Furthermore, data imbalance and label noise reduce robustness, especially for rare cancer subtypes. These technical limits underscore the importance of prioritizing multi-institutional training, external validation, and robustness testing during distribution adjustments rather than relying exclusively on peak accuracy measurements [90].

8.2 Interpretability

Building on these technical limits, the opacity of sophisticated AI models poses a second fundamental challenge: interpretability. The rising use of complex DL architectures has raised issues about model interpretability, particularly in high-stakes cancer decision-making. While many AI systems exhibit excellent prediction performance, their opaque decision-making procedures undermine physician trust and prevent real clinical monitoring [91]. Current explainability approaches are frequently ad hoc and poorly connected with therapeutic thinking. In the lack of visible and interpretable results, doctors may be hesitant to incorporate AI advice into treatment plans [92]. As a result, interpretability must be reframed as a core clinical requirement, with future models designed to provide actionable, auditable explanations that align with established diagnostic and therapeutic frameworks [93].

8.3 Ethical and Legal Concerns

The difficulty in comprehending AI output is closely related to bigger ethical and legal considerations. Ethical and legal concerns continue to pose significant hurdles to the proper use of AI in oncology. Bias caused by non-representative training data can worsen existing inequities in cancer diagnosis and treatment, especially in underrepresented communities and low-resource settings [94]. Furthermore, unanswered problems about data ownership, patient permission, accountability, and liability impede clinical implementation [95]. The absence of defined regulatory processes and ethical governance frameworks creates uncertainty for healthcare organizations and clinicians [96]. Transparent bias assessment, equity-aware model development, and standardized legal and regulatory standards that strike a balance between innovation and patient safety and rights are all necessary to address these issues [97].

8.4 Clinical Validation and Adoption

Finally, even after considering technological performance, interpretability, and ethical considerations, clinical validation remains a significant hurdle. The gap between technical validation and therapeutic benefit is a significant barrier to widespread clinical acceptance. Most AI systems are evaluated using retrospective performance metrics, with little evidence of their impact on patient outcomes, clinical workflows, or cost-effectiveness [98]. Even systems that show high concordance with expert recommendations often fail to influence real-world decision-making. Furthermore, integration into existing clinical workflows remains inadequate, exacerbated by physicians' insufficient AI literacy and infrastructure constraints in healthcare systems. Future efforts must prioritize prospective, impact-driven clinical trials and implementation studies that assess AI tools as components of routine oncology care rather than isolated technologies [99].

9. Future Directions

9.1 Emerging Trends

As AI advances, emerging trends promise to make cancer care more proactive and individualized. To put these trends into practice, actionable methods are required. Future study should leverage generative models (GANs, LLMs) to create synthetic datasets for uncommon tumors, supplementing limited data while protecting patient privacy. Validation should include cross-institutional performance testing to verify generalizability [100]. Transfer learning: Models trained on general radiology datasets can be fine-tuned for smaller, disease-specific cohorts. Studies should rigorously evaluate fine-tuning procedures and measure performance increases while reducing extra data requirements [101]. Multi-institutional cooperation should use federated learning frameworks. To preserve patient confidentiality, implement safe aggregation procedures, model update validation, and privacy-preserving audits [102]. Multi-modal AI: Using attention mechanisms or graph-based networks, researchers should create architectures that include heterogeneous data types (imaging, genomics, and EHRs), and then evaluate predicted accuracy and interpretability in clinical simulations. Patient-facing AI (wearables, chatbots): Deployment studies should analyze real-time monitoring, alarm thresholds, and usability, as well as incorporate patient feedback loops to optimize adoption [103]. AI in robotics: Clinical trials should examine AI-assisted robotic interventions in surgery and rehabilitation, measuring both procedural precision and workflow efficiency [104].

9.2 Healthcare Implications

Adoption of AI requires operational plans to optimize effectiveness and therapeutic advantages: Workflow automation: Use AI-powered task management systems to prioritize patients, generate reports automatically, and draw attention to unusual discoveries. Improvements in throughput, mistake reduction, and clinician satisfaction should all be measured in pilot studies [105]. Decision support systems: Create multi-modal AI systems that incorporate confidence rating and uncertainty quantification so medical professionals may assess recommendations in complicated situations [106]. Allocate resources by using predictive analytics models to estimate personnel, bed occupancy, and equipment requirements. Retrospective and prospective simulations should serve as the foundation for validation in order to maximize resource allocation in scenarios with fluctuating demand [107]. Training and workforce preparedness: Include data literacy, algorithmic reasoning, and AI auditing techniques in continuing professional education courses and medical curricula. Research should assess how learning outcomes and clinical decision-making are affected. Equitable deployment: Test AI diagnoses enabled by telemedicine in underprivileged areas. Assess patient outcomes, diagnostic precision, and accessibility advancements to guarantee equitable AI benefit distribution [108].

9.3 Research Priorities and Actionable Methods

To fully grasp AI's potential in oncology, research must be focused, methodologically rigorous, and therapeutically aligned. Bias mitigation: In addition to identifying biased datasets, employ bias correction strategies before, during, and after processing, as well as conduct subgroup performance audits [109]. Interpretability: Transition from post-hoc explanation methods (such as saliency maps) to inherently interpretable structures, such as attention-based, concept-based, or prototype-guided models that give explanations aligned with clinical reasoning [110]. Equitable access: Assess cloud-based, mobile, or edge-computing AI solutions in low-resource contexts using measures for usability, scalability, and clinical impact. Collaborative Development: Establish multidisciplinary AI innovation hubs that bring together clinicians, data scientists, engineers, and patient advocates. Measure success by clinical adoption, safety, and algorithmic performance [111]. Standards and reproducibility: Develop open access, curate multimodal datasets and use standardized evaluation processes across universities. Encourage participation in competitions, such as DREAM and MICCAI, to measure performance and reproducibility [112]. Clinical validation and implementation: Combine algorithmic development with prospective, randomized, or pragmatic studies to assess patient outcomes, workflow integration, cost-effectiveness, and regulatory compliance [113].

10. Conclusion

AI is revolutionizing cancer diagnosis, treatment, and care by analyzing complex healthcare data with pinpoint accuracy. It improves imaging and histology, facilitates genomic-based diagnostics, allows for tailored treatment plans, speeds up medication discovery, and improves surgical planning and patient monitoring. Despite its potential, issues such as data privacy, algorithmic bias, inadequate clinical validation, fragmented healthcare systems, and a lack of AI knowledge among professionals impede broad implementation. To overcome these constraints, clinicians, data scientists, engineers, ethicists, policymakers, and patients must work together across disciplines, as well as invest in research infrastructure, education, and international data exchange. With proper integration, AI has the potential to make oncology more precise, preventive, equitable, and patient-centered, making it a formidable partner in the global fight against cancer.

Conflict of Interest

The authors declare no conflict of interest.

Generative AI Statement

The authors declare that no Gen AI was used in the creation of this manuscript.

References

[1] Ghufran MS, Soni P, Duddukuri GR. The global concern for cancer emergence and its prevention: A systematic unveiling of the present scenario, in Bioprospecting of tropical medicinal plants. Handbook of Cancer and Public Health. Cham: Springer Nature, 2023, 1429-1455. DOI: 10.1007/978-3-031-28780-0_60

[2] Feng X, Shu W, Li M, Li J, Xu J, He M. Pathogenomics for accurate diagnosis, treatment, prognosis of oncology: A cutting edge overview. Journal of Translational Medicine, 2024, 22(1), 131. DOI: 10.1186/s12967-024-04915-3

[3] Lee D, Yoon SN. Application of artificial intelligence-based technologies in the healthcare industry: Opportunities and challenges. International Journal of Environmental Research and Public Health, 2021, 18(1), 271. DOI: 10.3390/ijerph18010271

[4] Sebastian AM, Peter D. Artificial intelligence in cancer research: Trends, challenges and future directions. Life, 2022, 12(12), 1991. DOI: 10.3390/life12121991

[5] Fitzgerald RC, Antoniou AC, Fruk L, Rosenfeld N. The future of early cancer detection. Nature Medicine, 2022, 666-677. DOI: 10.1038/s41591-022-01746-x

[6] Chen YM, Hsiao TH, Lin CH, Fann YC. Unlocking precision medicine: Clinical applications of integrating health records, genetics, and immunology through artificial intelligence. Journal of Biomedical Science, 2025, 32(1), 16. DOI: 10.1186/s12929-024-01110-w

[7] Panagoulias DP, Tsihrintzis GA, Virvou M. Challenges in regulating and validating AI-driven healthcare. Artificial Intelligence-empowered Bio-medical Applications. Cham: Springer Nature, 2025, 135-152. DOI: 10.1007/978-3-031-90174-4_6

[8] Elemento O, Leslie C, Lundin J, Tourassi G. Artificial intelligence in cancer research, diagnosis and therapy. Nature Reviews Cancer, 2021, 21(12), 747-752. DOI: 10.1038/s41568-021-00399-1

[9] Taylor LA, Nong P, Platt J. Fifty years of trust research in health care: A synthetic review. The Milbank Quarterly, 2023, 101(1), 126-178. DOI: 10.1111/1468-0009.12598

[10] Calleja-Sanz G, Olivella-Nadal J, Solé-Parellada F. Technology forecasting: Recent trends and new methods. Research Methodology in Management and Industrial Engineering. Cham: Springer Nature, 2020, 45-69. DOI: 10.1007/978-3-030-40896-1_3

[11] Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, et al. Early detection of cancer. Science, 2022, 375(6586), eaay9040. DOI: 10.1126/science.aay9040

[12] Jiang X, Hu Z, Wang S, Zhang Y. Deep learning for medical image-based cancer diagnosis. Cancers, 2023, 15(14), 3608. DOI: 10.3390/cancers15143608

[13] Mallum A, Mkhize T, Akudugu JM, Ngwa W, Vorster M. The role of positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning: A literature review. Diagnostics, 2022, 13(1), 53. DOI: 10.3390/diagnostics13010053

[14] Alzubaidi L, Zhang J, Humaidi AJ, Al-Dujaili A, Duan Y, Al-Shamma O, et al. Review of deep learning: Concepts, CNN architectures, challenges, applications, future directions. Journal of Big Data, 2021, 8(1), 53. DOI: 10.1186/s40537-021-00444-8

[15] Davoodi P, Ezoji M, Sadeghnejad N. Classification of natural images inspired by the human visual system. Neurocomputing, 2023, 518, 60-69. DOI: 10.1016/j.neucom.2022.10.055

[16] McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et al. International evaluation of an AI system for breast cancer screening. Nature, 2020, 577(7788), 89-94. DOI: 10.1038/s41586-019-1799-6

[17] Grenier PA, Brun AL, Mellot F. The potential role of artificial intelligence in lung cancer screening using low-dose computed tomography. Diagnostics, 2022, 12(10), 2435. DOI: 10.3390/diagnostics12102435

[18] Homayounieh F, Digumarthy S, Ebrahimian S, Rueckel J, Hoppe BF, Sabel BO, et al. An artificial intelligence-based chest X-ray model on human nodule detection accuracy from a multicenter study. JAMA Network Open, 2021, 4(12), e2141096. DOI: 10.1001/jamanetworkopen.2021.41096

[19] Chaddad A, Tan G, Liang X, Hassan L, Rathore S, Desrosiers C, et al. Advancements in MRI-based radiomics and artificial intelligence for prostate cancer: A comprehensive review and future prospects. Cancers, 2023, 15, 3839. DOI: 10.3390/cancers15153839

[20] Bahadir CD, Omar M, Rosenthal J, Marchionni L, Liechty B, Pisapia DJ, et al. Artificial intelligence applications in histopathology. Nature Reviews Electrical Engineering, 2024. 1(2), 93-108. DOI: 10.1038/s44287-023-00012-7

[21] Shafi S, Parwani AV. Artificial intelligence in diagnostic pathology. Diagnostic Pathology, 2023, 18(1), 109. DOI: 10.1186/s13000-023-01375-z

[22] Singhal N, Soni S, Bonthu S, Chattopadhyay N, Samanta P, Joshi U, et al. A deep learning system for prostate cancer diagnosis and grading in whole slide images of core needle biopsies. Scientific Reports, 2022, 12(1), 3383. DOI: 10.1038/s41598-022-07217-0

[23] Khalighi S, Reddy K, Midya A, Pandav KB, Madabhushi A, Abedalthagafi M. Artificial intelligence in neuro-oncology: Advances and challenges in brain tumor diagnosis, prognosis, and precision treatment. npj Precision Oncology, 2024, 8(1), 80. DOI: 10.1038/s41698-024-00575-0

[24] Romanò M. The meanings of prognosis: When and how to discuss it? Palliative Care in Cardiac Intensive Care Units. Cham: Springer International Publishing, 2021, 67-81. DOI: 10.1007/978-3-030-80112-0_4

[25] Teh BT, Fearon ER. 14-Genetic and epigenetic alterations in cancer. Abeloff's Clinical Oncology (Sixth Edition), 2020, 209-224. e2. DOI: 10.1016/B978-0-323-47674-4.00014-1.

[26] Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G, Rawool S, et al. Next-generation sequencing technology: Current trends and advancements. Biology, 2023, 12(7), 997. DOI: 10.3390/biology12070997

[27] Mukherjee A, Abraham S, Singh A, Balaji S, Mukunthan KS. From data to cure: A comprehensive exploration of multi-omics data analysis for targeted therapies. Molecular Biotechnology, 2025, 67(4), 1269-1289. DOI: 10.1007/s12033-024-01133-6
[28] Wei L, Niraula D, Gates EDH, Fu J, Luo Y, Nyflot MJ, et al. Artificial intelligence (AI) and machine learning (ML) in precision oncology: A review on enhancing discoverability through multiomics integration. British Journal of Radiology, 2023, 96(1150), 20230211. DOI: 10.1259/bjr.20230211
[29] Ben-Hamo R, Jacob Berger A, Gavert N, Miller M, Pines G, Oren R, et al. Predicting and affecting response to cancer therapy based on pathway-level biomarkers. Nature Communications, 2020, 11(1), 3296. DOI: 10.1038/s41467-020-17090-y
[30] Roy S, Kumar R, Mittal V, Gupta D. Classification models for Invasive Ductal Carcinoma Progression, based on gene expression data-trained supervised machine learning. Scientific Reports, 2020, 10(1), 4113. DOI: 10.1038/s41598-020-60740-w
[31] Ali H. Artificial intelligence in multi-omics data integration: Advancing precision medicine, biomarker discovery and genomic-driven disease interventions. International Journal of Science and Research Archive, 2023, 8(1), 1012-1030. DOI: 10.30574/ijsra.2023.8.1.0189
[32] Yetgin A. Revolutionizing multi-omics analysis with artificial intelligence and data processing. Quantitative Biology, 2025, 13(3), e70002. DOI: 10.1002/qub2.70002
[33] Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: Pathogenesis and treatments. Signal Transduction and Targeted Therapy, 2025, 10(1), 49. DOI: 10.1038/s41392-024-02108-4
[34] Khazeeva G, Sablauskas K, van der Sanden B, Steyaert W, Kwint M, Rots D, et al. DeNovoCNN: A deep learning approach to de novo variant calling in next generation sequencing data. Nucleic Acids Research, 2022, 50(17), e97. DOI: 10.1093/nar/gkac511
[35] Kudłacik-Kramarczyk S, Kieres W, Przybyłowicz A, Ziejewska C, Marczyk J, Krzan M. Recent advances in micro-and nano-enhanced intravascular biosensors for real-time monitoring, early disease diagnosis, and drug therapy monitoring. Sensors, 2025, 25(15), 4855. DOI: 10.3390/s25154855
[36] Tsimberidou AM, Kahle M, Vo HH, Baysal MA, Johnson A, Meric-Bernstam F. Molecular tumour boards-current and future considerations for precision oncology. Nature Reviews Clinical Oncology, 2023, 20(12), 843-863. DOI: 10.1038/s41571-023-00824-4
[37] Tiwari A, Mishra S, Kuo TR. Current AI technologies in cancer diagnostics and treatment. Molecular Cancer, 2025, 24(1), 159. DOI: 10.1186/s12943-025-02369-9
[38] Kann BH, Hosny A, Aerts HJWL. Artificial intelligence for clinical oncology. Cancer Cell, 2021, 39(7), 916-927. DOI: 10.1016/j.ccell.2021.04.002
[39] Wang L, Chen X, Zhang L, Li L, Huang Y, Sun Y, et al. Artificial intelligence in clinical decision support systems for oncology. International Journal of Medical Sciences, 2023, 20(1), 79-86. DOI: 10.7150/ijms.77205
[40] Jie Z, Zhiying Z, Li L. A meta-analysis of Watson for Oncology in clinical application. Scientific Reports, 2021, 11(1), 5792. DOI: 10.1038/s41598-021-84973-5
[41] Kulavi S, Ghosh C, Saha M, Chatterjee S. One size does not fit all: An overview of personalized treatment in cancer. Journal of Pharmaceutical Research International, 2021, 33(28A), 87-103. DOI: 10.9734/JPRI/2021/v33i28A31513
[42] Mei T, Wang T, Zhou Q. Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients. Clinical and Experimental Medicine, 2024, 24(1), 60. DOI: 10.1007/s10238-024-01324-0
[43] Bonci EA, Bandura A, Dooley A, Erjan A, Gebreslase HW, Hategan M, et al. Artificial intelligence in NSCLC management for revolutionizing diagnosis, prognosis, and treatment optimization: A systematic review. Critical Reviews in Oncology/Hematology, 2025, 216, 104929. DOI: 10.1016/j.critrevonc.2025.104929
[44] Fahim YA, Hasani IW, Kabba S, Ragab WM. Artificial intelligence in healthcare and medicine: Clinical applications, therapeutic advances, and future perspectives. European Journal of Medical Research, 2025, 30(1), 848. DOI: 10.1186/s40001-025-03196-w
[45] Gardner SJ, Kim J, Chetty IJ. Modern radiation therapy planning and delivery. Hematology/Oncology Clinics of North America, 2019, 33(6), 947-962. DOI: 10.1016/j.hoc.2019.08.005
[46] Kalantar R, Lin G, Winfield JM, Messiou C, Lalondrelle S, Blackledge MD, et al. Automatic segmentation of pelvic cancers using deep learning: State-of-the-art approaches and challenges. Diagnostics, 2021, 11(11), 1964. DOI: 10.3390/diagnostics11111964
[47] Ng CKC. Performance of commercial deep learning-based auto-segmentation software for prostate cancer radiation therapy planning: A systematic review. Information, 2025, 16(3), 215. DOI: 10.3390/info16030215
[48] Garcıa S, Menghi C, Pelliccione P, Berger T, Wohlrab R. An architecture for decentralized, collaborative, and autonomous robots. 2018 IEEE International Conference on Software Architecture (ICSA). IEEE, 2018, 75-7509. DOI: 10.1109/ICSA.2018.00017
[49] Duchateau N, Puyol-Antón E, Ruijsink B, King A. AI and machine learning: The basics. AI and Big Data in Cardiology. Cham: Springer International Publishing, 2023, 11-33. DOI: 10.1007/978-3-031-05071-8_2
[50] Ghodke BS. The role of AI in enhancing healthcare quality and safety. International Journal of Innovative Research in Science, Engineering and Technology, 2024, 13(12), 20807-20815. DOI: 10.15680/IJIRSET.2024.1312200
[51] Kok Wah JN. AI-driven robotic surgery in oncology: Advancing precision, personalization, and patient outcomes. Journal of Robotic Surgery, 2025, 19(1), 382. DOI: 10.1007/s11701-025-02555-3
[52] Das P, Ganguly S, Margel S, Gedanken A. Tailor made magnetic nanolights: Fabrication to cancer theranostics applications. Nanoscale Advances, 2021, 3(24), 6762-6796. DOI: 10.1039/d1na00447f
[53] Fan X, Liu X, Xia Q, Chen G, Cheng J, Shi Z, et al. Advanced image-guidance and surgical-navigation techniques for real-time visualized surgery. Advanced Science, 2025, 12(41), e09294. DOI: 10.1002/advs.202509294
[54] Iftikhar M, Saqib M, Zareen M, Mumtaz H. Artificial intelligence: Revolutionizing robotic surgery: Review. Annals of Medicine and Surgery, 2024, 86(9), 5401-5409. DOI: 10.1097/MS9.0000000000002426
[55] Guni A, Varma P, Zhang J, Fehervari M, Ashrafian H. Artificial intelligence in surgery: The future is now. European Surgical Research, 2024, 65(1), 22-39. DOI: 10.1159/000536393

[56] Yangi K, On TJ, Xu Y, Gholami AS, Hong J, Reed AG, et al. Artificial intelligence integration in surgery through hand and instrument tracking: A systematic literature review. Frontiers in Surgery, 2025, 12, 1528362. DOI: 10.3389/fsurg.2025.1528362
[57] Kondylakis H, Axenie C, Kiran Bastola D, Katehakis DG, Kouroubali A, Kurz D, et al. Status and recommendations of technological and data-driven innovations in cancer care: Focus group study. Journal of Medical Internet Research, 2020, 22(12), e22034. DOI: 10.2196/22034
[58] Gentile F, Yaacoub JC, Gleave J, Fernandez M, Ton AT, Ban F, et al. Artificial intelligence-enabled virtual screening of ultra-large chemical libraries with deep docking. Nature Protocols, 2022, 17(3), 672-697. DOI: 10.1038/s41596-021-00659-2
[59] Carpenter KA, Huang X. Machine learning-based virtual screening and its applications to Alzheimer's drug discovery: A review. Current Pharmaceutical Design, 2018, 24(28), 3347-3358. DOI: 10.2174/1381612824666180607124038
[60] Upadhyaya V. Predictive analytics in medical diagnosis. Intelligent Data Analytics for Bioinformatics and Biomedical Systems, 2024, 27-66. DOI: 10.1002/9781394270910.ch2
[61] Bhatia A, Kumar A, Kumar R, Jain V. Medications and the role of tailored healthcare. Smart Healthcare, Clinical Diagnostics, and Bioprinting Solutions for Modern Medicine. Hershey: IGI Global Scientific Publishing, 2025, 165-192. DOI: 10.4018/979-8-3373-0659-9.ch009
[62] Mango VL, Sun M, Wynn RT, Ha R. Should we ignore, follow, or biopsy? Impact of artificial intelligence decision support on breast ultrasound lesion assessment. American Journal of Roentgenology, 2020, 214(6), 1445-1452. DOI: 10.2214/AJR.19.21872
[63] Tsoupras G, Syed ZA. AI-driven decision support systems for early breast cancer detection: Adoption implications in healthcare contexts. Lund: Lund University, 2025.
[64] Badawy E, ElNaggar R, Soliman SAM, Elmesidy DS. Performance of AI-aided mammography in breast cancer diagnosis: Does breast density matter? Egyptian Journal of Radiology and Nuclear Medicine, 2023, 54(1), 178. DOI: 10.1186/s43055-023-01129-3
[65] Agrawal S, Vagha S. A comprehensive review of artificial intelligence in prostate cancer care: State-of-the-art diagnostic tools and future outlook. Cureus, 2024, 16(8), e66225. DOI: 10.7759/cureus.66225
[66] Nasir ES, Parvaiz A, Fraz MM. Nuclei and glands instance segmentation in histology images: A narrative review. Artificial Intelligence Review, 2023, 56(8), 7909-7964. DOI: 10.1007/s10462-022-10372-5
[67] Arita Y, Roest C, Kwee TC, Paudyal R, Lema-Dopico A, Fransen S, et al. Advancements in artificial intelligence for prostate cancer: Optimizing diagnosis, treatment, and prognostic assessment. Asian Journal of Urology, 2025, 12(4), 434-444. DOI: 10.1016/j.ajur.2024.12.001
[68] Xu Q, Zhai JC, Huo CQ, Li Y, Dong XJ, Li DF, et al., OncoPDSS: An evidence-based clinical decision support system for oncology pharmacotherapy at the individual level. BMC cancer, 2020, 20(1), 740. DOI: 10.1186/s12885-020-07221-5
[69] Magrabi F, Ammenwerth E, McNair JB, De Keizer NF, Hyppönen H, Nykänen P, et al. Artificial intelligence in clinical decision support: Challenges for evaluating AI and practical implications. Yearbook of Medical Informatics, 2019, 28(1), 128-134. DOI: 10.1055/s-0039-1677903
[70] Singh RP, Hom GL, Abramoff MD, Campbell JP, Chiang MF, on behalf of the AAO Task Force on Artificial Intelligence. Current challenges and barriers to real-world artificial intelligence adoption for the healthcare system, provider, and the patient. Translational Vision Science & Technology, 2020, 9(2), 45. DOI: 10.1167/tvst.9.2.45
[71] Yao S, Wang R, Qian K, Zhang Y. Real world study for the concordance between IBM Watson for Oncology and clinical practice in advanced non-small cell lung cancer patients at a lung cancer center in China. Thorac Cancer, 2020, 11(5), 1265-1270. DOI: 10.1111/1759-7714.13391
[72] Jiang B, Ozkara BB, Zhu G, Boothroyd D, Allen JW, Barboriak DP, et al. Assessing the performance of artificial intelligence models: Insights from the American Society of Functional Neuroradiology Artificial Intelligence Competition. AJNR American Journal of Neuroradiology, 2024, 45(9), 1276-1283. DOI: 10.3174/ajnr.A8317
[73] Ripatti AR. Screening diabetic retinopathy and age-related macular degeneration with artificial intelligence: New innovations for eye care. Oulu: Oulun ammattikorkeakoulu, 2025.
[74] Skevas C, de Olaguer NP, Lleó A, Thiwa D, Schroeter U, Lopes IV, et al. Implementing and evaluating a fully functional AI-enabled model for chronic eye disease screening in a real clinical environment. BMC Ophthalmology, 2024, 24(1), 51. DOI: 10.1186/s12886-024-03306-y
[75] Saravi B, Hassel F, Ülkümen S, Zink A, Shavlokhova V, Couillard-Despres S, et al. Artificial intelligence-driven prediction modeling and decision making in spine surgery using hybrid machine learning models. Journal of Personalized Medicine, 2022, 12(4), 509. DOI: 10.3390/jpm12040509
[76] Wang S, Liu J, Song L, Wen W, Huang J, Peng Y. Over-detection and over-surveillance in breast screening: Current status and the potential for artificial intelligence optimisation. Insights into Imaging, 2025, 16(1), 276. DOI: 10.1186/s13244-025-02160-w
[77] Xu B, Zhou F. The roles of cloud-based systems on the cancer-related studies: A systematic literature review. IEEE Access, 2022, 10, 64126-64145. DOI: 10.1109/ACCESS.2022.3181147
[78] Zhang X, Yang L, Liu C, Yuan X, Zhang Y. An artificial intelligence pipeline for hepatocellular carcinoma: From data to treatment recommendations. International Journal of General Medicine, 2025, 18, 3581-3595. DOI: 10.2147/IJGM.S529322
[79] Wah JNK. Revolutionizing surgery: AI and robotics for precision, risk reduction, and innovation. Journal of Robotic Surgery, 2025, 19(1), 47. DOI: 10.1007/s11701-024-02205-0
[80] Reva T, Reva T, Nizhenkovskyi O, Chkhalo O. A comparison study of artificial intelligence-driven no-code applications for drug discovery and development. ScienceRise: Pharmaceutical Science, 2024, 6(52), 80-89. DOI: 10.15587/2519-4852.2024.318920
[81] Tupasela A, Di Nucci E. Concordance as evidence in the Watson for Oncology decision-support system. Ai & Society, 2020, 35(4), 811-818. DOI: 10.1007/s00146-020-00945-9
[82] Subhan A, Manoharan G. Advancing cancer care through artificial intelligence: From innovative models to clinical decision-making and regulatory integration. Clinical Cancer Bulletin, 2025, 4(1), 23. DOI: 10.1007/s44272-025-00052-0
[83] Fatima G, Alhmadi H, Ali Mahdi A, Hadi N, Fedacko J, Magomedova A, et al. Transforming diagnostics: A comprehensive review of advances in digital pathology. Cureus, 2024, 16(10), e71890. DOI: 10.7759/cureus.71890

[84] Hamrouni J. Predictive modelling for clinical trial completion: Assessing the phase success-incorporating RAG techniques for predictive modelling of clinical trial outcomes. Universidade NOVA de Lisboa, 2024
[85] Cheng CH, Shi SS. Artificial intelligence in cancer: Applications, challenges, and future perspectives. Molecular Cancer, 2025, 24(1), 274. DOI: 10.1186/s12943-025-02450-3
[86] Srivastav AK, Singh A, Singh S, Rivers B, Lillard JW Jr, Singh R. Revolutionizing oncology through AI: Addressing cancer disparities by improving screening, treatment, and survival outcomes via integration of social determinants of health. Cancers, 2025, 17(17), 2866. DOI: 10.3390/cancers17172866
[87] Baweja B, Vats P, Kausik S, Singh J, Nema R, Yadav P. Challenges and limitations of computational methods in oncology. Advances in Cancer Detection, Prediction, and Prognosis Using Artificial Intelligence and Machine Learning. Singapore: Springer Nature Singapore, 2025, 307-324. DOI: 10.1007/978-981-96-9346-7_13
[88] Kaur P, Chand T, Rani S. Integration of artificial intelligence in laryngeal cancer diagnosis and prognosis: A comparative analysis bridging traditional medical practices with modern computational techniques. Archives of Computational Methods in Engineering, 2025, 1-37. DOI: 10.1007/s11831-025-10368-8
[89] Ramchandani R, Guo E, Biglou SG, Sabbah SG, Mostowy M, Mahiny D, et al. Representation and bias in artificial intelligence models for thyroid cancer: A systematic review. Thyroid, 2025, 35(12), 1391-1402. DOI: 10.1177/10507256251372175
[90] Guidotti R, Monreale A, Ruggieri S, Turini F, Giannotti F, Pedreschi D, et al. A survey of methods for explaining black box models. ACM Computing Surveys, 2018, (5), 1-42. DOI: 10.1145/3236009
[91] Emma L. Explainable AI for high-stakes decision making in healthcare. Ladoke Akintola University of Technology, 2024.
[92] Rudin C, Chen C, Chen Z, Huang H, Semenova L, Zhong C. Interpretable machine learning: Fundamental principles and 10 grand challenges. Statistic Surveys, 2022, 16, 1-85. DOI: 10.1214/21-SS133
[93] Chandak T, Jayashree J, Vijayashree J. Trends and advancements of AI and XAI in drug discovery. Explainable AI (XAI) for sustainable development. Boca Raton, FL: CRC Press, 2024, 233-255.
[94] Dziedzic A, Issa J, Chaurasia A, Tanasiewicz M. Artificial intelligence and health-related data: The patient's best interest and data ownership dilemma. Proceedings of the Institution of Mechanical Engineers, 2024, 238(10), 1023-1028. DOI: 10.1177/09544119241279630
[95] Norori N, Hu Q, Aellen FM, Faraci FD, Tzovara A. Addressing bias in big data and AI for health care: A call for open science. Patterns, 2021, 2(10), 100347. DOI: 10.1016/j.patter.2021.100347
[96] Gladwin O. Human rights in the age of AI: Establishing fairness and accountability through algorithmic governance. 2024. DOI: 10.13140/RG.2.2.13279.06567
[97] Mennella C, Maniscalco U, De Pietro G, Esposito M. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. Heliyon, 2024, 10(4), e26297. DOI: 10.1016/j.heliyon.2024.e26297
[98] Arvai N, Katonai G, Mesko B. Health care professionals' concerns about medical AI and psychological barriers and strategies for successful implementation: Scoping review. Journal of Medical Internet Research, 2025, 27, e66986. DOI: 10.2196/66986
[99] Oualikene-Gonin W, Jaulent MC, Thierry JP, Oliveira-Martins S, Belgodère L, Maison P, et al. Artificial intelligence integration in the drug lifecycle and in regulatory science: Policy implications, challenges and opportunities. Frontiers in Pharmacology, 2024, 15, 1437167. DOI: 10.3389/fphar.2024.1437167
[100] Koc C, Özyurt F, Iantovics LB. Survey on latest advances in natural language processing applications of generative adversarial networks. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery, 2025, 15(1), e70004. DOI: 10.1002/widm.70004
[101] Preuss K, Thach N, Liang X, Baine M, Chen J, Zhang C, et al. Using quantitative imaging for personalized medicine in pancreatic cancer: A review of radiomics and deep learning applications. Cancers, 2022, 14(7), 1654. DOI: 10.3390/cancers14071654
[102] Feretzakis G, Papaspyridis K, Gkoulalas-Divanis A, Verykios VS. Privacy-preserving techniques in generative AI and large language models: A narrative review. Information, 2024, 15(11), 697. DOI: 10.3390/info15110697
[103] Khan AOR, Islam SM, Sarkar A, Islam T, Paul R, Bari MS. Real-time predictive health monitoring using AI-driven wearable sensors: Enhancing early detection and personalized interventions in chronic disease management. International Journal for Multidisciplinary Research, 2024, 6(5), 1-21. DOI: 10.36948/ijfmr.2024.v06i05.28497
[104] Thacharodi A, Singh P, Meenatchi R, Tawfeeq Ahmed ZH, Kumar RRS, VN, et al. Revolutionizing healthcare and medicine: The impact of modern technologies for a healthier future-A comprehensive review. Health Care Science, 2024, 3(5), 329-349. DOI: 10.1002/hcs2.115
[105] Govindaraj M, Khan P, Krishnan R, Gnanasekaran C, Lawrence J. Revolutionizing healthcare: The transformative impact of artificial intelligence. Revolutionizing the healthcare sector with AI. Hershey: IGI Global Scientific Publishing, 2024, 54-78. DOI: 10.4018/979-8-3693-3731-8.ch003
[106] Tello M, Reich ES, Puckey J, Maff R, Garcia-Arce A, Bhattacharya BS, Feijoo F. Machine learning based forecast for the prediction of inpatient bed demand. BMC Medical Informatics and Decision Making, 2022, 22(1), 55. DOI: 10.1186/s12911-022-01787-9
[107] Areia M, Mori Y, Correale L, Repici A, Bretthauer M, Sharma P, et al. Cost-effectiveness of artificial intelligence for screening colonoscopy: A modelling study. The Lancet Digital Health, 2022, 4(6), e436-e444. DOI: 10.1016/S2589-7500(22)00042-5
[108] Zhang DY, Venkat A, Khasawneh H, Sali R, Zhang V, Pei Z. Implementation of digital pathology and artificial intelligence in routine pathology practice. Laboratory Investigation, 2024, 104(9), 102111. DOI: 10.1016/j.labinv.2024.102111
[109] Balahur A, Jenet A, Hupont IT, Charisi V, Ganesh A, Griesinger CB, et al. Data quality requirements for inclusive, non-biased and trustworthy AI. 2022. DOI: 10.2760/365479
[110] Kalasampath K, Spoorthi KN, Sajeev S, Kuppa SS, Ajay K, Maruthamuthu A. A Literature review on applications of explainable artificial intelligence (XAI). IEEE Access, 2025, 13, 41111-41140. DOI: 10.1109/ACCESS.2025.3546681
[111] Greco L, Percannella G, Ritrovato P, Tortorella F, Vento M. Trends in IoT based solutions for health care: Moving AI to the edge. Pattern Recognition Letters, 2020, 135, 346-353. DOI: 10.1016/j.patrec.2020.05.016
[112] Wang Z, Davidsen TM, Kuffel GR, Addepalli K, Bell A, Casas-Silva E, et al. NCI cancer research data commons: Resources to share key cancer data. Cancer Research, 2024, 84(9), 1388-1395. DOI: 10.1158/0008-5472.CAN-23-2468
[113] Garcia-Saiso S, Marti M, Pesce K, Luciani S, Mujica O, Hennis A, et al. Artificial intelligence as a potential catalyst to a more equitable cancer care. JMIR Cancer, 2024, 10, e57276. DOI: 10.2196/57276